HUE028878T2 - CLEC14A inhibitors - Google Patents

CLEC14A inhibitors Download PDF

Info

Publication number
HUE028878T2
HUE028878T2 HUE10757617A HUE10757617A HUE028878T2 HU E028878 T2 HUE028878 T2 HU E028878T2 HU E10757617 A HUE10757617 A HU E10757617A HU E10757617 A HUE10757617 A HU E10757617A HU E028878 T2 HUE028878 T2 HU E028878T2
Authority
HU
Hungary
Prior art keywords
clec14a
antibody
inhibitor
compound
polypeptide
Prior art date
Application number
HUE10757617A
Other languages
English (en)
Hungarian (hu)
Inventor
Roy Bicknell
Xiaodong Zhuang
Manuela Mura
Original Assignee
Cancer Res Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Tech Ltd filed Critical Cancer Res Tech Ltd
Publication of HUE028878T2 publication Critical patent/HUE028878T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE10757617A 2009-09-03 2010-09-03 CLEC14A inhibitors HUE028878T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23958409P 2009-09-03 2009-09-03

Publications (1)

Publication Number Publication Date
HUE028878T2 true HUE028878T2 (en) 2017-01-30

Family

ID=43333027

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10757617A HUE028878T2 (en) 2009-09-03 2010-09-03 CLEC14A inhibitors

Country Status (8)

Country Link
US (1) US9255148B2 (cg-RX-API-DMAC7.html)
EP (1) EP2473529B1 (cg-RX-API-DMAC7.html)
JP (1) JP5962996B2 (cg-RX-API-DMAC7.html)
AU (1) AU2010290989B2 (cg-RX-API-DMAC7.html)
CA (1) CA2810119C (cg-RX-API-DMAC7.html)
ES (1) ES2567030T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028878T2 (cg-RX-API-DMAC7.html)
WO (1) WO2011027132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187556A1 (en) * 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
EP3430050A1 (en) * 2016-03-15 2019-01-23 Cancer Research Technology Limited Antibodies and related molecules and uses thereof
AU2017232431A1 (en) * 2016-03-15 2018-09-20 Cancer Research Technology Limited Chimeric antigen receptor
CA3035723A1 (en) * 2016-09-08 2018-03-15 Woori Technologies Corporation Deglycosylated antibody specifically binding to clec14a and uses thereof
CN113332448B (zh) * 2017-03-17 2023-08-08 浙江孚诺医药股份有限公司 肿瘤靶向多肽、制备方法及其应用
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030092002A1 (en) 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
US6894148B2 (en) 1997-11-12 2005-05-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020015950A1 (en) 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
PT1623990E (pt) * 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
KR20050004240A (ko) * 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US7695959B2 (en) 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
ATE360068T1 (de) 2000-11-06 2007-05-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
AU2002257004A1 (en) * 2001-02-14 2002-10-15 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2003240495A1 (en) * 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
US20060099143A1 (en) 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
US8293710B2 (en) 2005-01-03 2012-10-23 Blue Blood Biotech Corp. Method for treating wounds using an EGF-like domain of thrombomodulin
US20060148695A1 (en) * 2005-01-03 2006-07-06 National Cheng Kung University Novel angiogenic composition and use thereof
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
BRPI0613227A2 (pt) * 2005-06-09 2011-01-04 Chiang Chuan Chi uma composição para cicatrização de ferida e uso desta

Also Published As

Publication number Publication date
ES2567030T3 (es) 2016-04-19
US9255148B2 (en) 2016-02-09
US20120276000A1 (en) 2012-11-01
EP2473529A1 (en) 2012-07-11
EP2473529B1 (en) 2016-02-10
WO2011027132A1 (en) 2011-03-10
JP2013503842A (ja) 2013-02-04
CA2810119A1 (en) 2011-03-10
AU2010290989B2 (en) 2016-05-19
JP5962996B2 (ja) 2016-08-03
CA2810119C (en) 2018-10-23
AU2010290989A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
JP5750433B2 (ja) 診断および治療のための腫瘍関連抗原の同定
US9150647B2 (en) Biological inhibitors of ROR1 capable of inducing cell death
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
EP2473529B1 (en) Clec14a inhibitors
CN108884168B (zh) 抗体及其相关分子和用途
KR101886890B1 (ko) 항인간 ccr7 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체
US11919959B2 (en) Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
US20060024233A1 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
JPWO2016133059A1 (ja) Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤
WO2009044158A2 (en) Inhibitors and uses
WO2016092301A1 (en) Vascular targeting
TW202535920A (zh) 程序性死亡配體1(pd-l1)嵌合抗原受體及其應用
KR20130047874A (ko) 골 손실 진단 마커로서의 피브리노겐의 용도